Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Below Fifty Day Moving Average – Should You Sell?

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.89 and traded as low as $2.56. Anavex Life Sciences shares last traded at $2.59, with a volume of 892,938 shares traded.

Analyst Ratings Changes

AVXL has been the topic of several research reports. Weiss Ratings downgraded Anavex Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw initiated coverage on Anavex Life Sciences in a research note on Monday, May 4th. They issued a “buy” rating and a $20.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and set a $24.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $21.33.

Anavex Life Sciences Price Performance

The firm has a market capitalization of $240.02 million, a P/E ratio of -5.63 and a beta of 1.20. The stock’s 50 day moving average is $2.89 and its two-hundred day moving average is $3.66.

Institutional Trading of Anavex Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $26,000. Quarry LP bought a new position in shares of Anavex Life Sciences in the 3rd quarter worth $36,000. Russell Investments Group Ltd. grew its stake in shares of Anavex Life Sciences by 11,540.0% during the third quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 6,924 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Anavex Life Sciences during the second quarter worth $95,000. Finally, HBW Advisory Services LLC bought a new stake in Anavex Life Sciences in the fourth quarter valued at about $40,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.